Agios Pharmaceuticals, Inc.
AGIO
$27.42
-$0.07-0.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -110.91% | -16.54% | -9.49% | -0.61% | 1,137.97% |
| Total Depreciation and Amortization | 2.16% | -20.97% | -5.19% | -2.57% | -17.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.31% | 114.66% | 39.79% | -49.84% | -3,607.25% |
| Change in Net Operating Assets | -100.51% | -18.18% | -25.94% | -926.09% | 1,778.50% |
| Cash from Operations | -4.67% | -6.25% | -11.64% | -83.71% | -36.62% |
| Capital Expenditure | -271.12% | -453.80% | -443.26% | -313.25% | -13.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 89.62% | 113.47% | -9.07% | -150.33% | 32.90% |
| Cash from Investing | -61.90% | 112.02% | -9.61% | -151.47% | 537.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 68.18% | -94.09% | -72.39% | 471.66% | 40.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 68.18% | -94.09% | -72.39% | 471.66% | 40.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -93.00% | 105.57% | -91.11% | -843.48% | 928.66% |